Description
A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial
Location: CPMC (San Francisco)
Please contact clinicalresearch@sutterhealth.org about the QED Cholangiocarcinoma Proof trial
View study details on ClinicalTrials.gov
Principal Investigator
Co-Investigator(s)
Recruitment Status
Active, Recruiting
Start Date
August 23, 2019